Skip to content

Usher Syndrome Type 2d C1568249

Published: July 22, 2026Updated: August 20, 2026

A genetic condition causing hearing loss and retinal degeneration, often linked to USH2A gene mutations. Symptoms typically appear in adolescence. Management is supportive, focusing on hearing and vision assistance.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q89.9
ICD-11
LA00.0
Body system
congenital
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(congenital)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Severe sensorineural hearing loss present at birth

(ear)

Retinitis pigmentosa

(eye)

Vestibular hypofunction

(nervous)

Photophobia

(eye)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Cochlear Implantation

Surgical placement of a device that bypasses damaged hair cells in the inner ear to provide direct electrical stimulation to the auditory nerve, enabling perception of sound. Requires thorough audiologic evaluation and neural imaging prior to the procedure.

surgical
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Regular Ophthalmologic Surveillance

Scheduled comprehensive eye examinations including visual field testing, electroretinography, and retinal imaging to monitor progression of retinitis pigmentosa and guide timing of interventions. Typically conducted annually or semi-annually depending on disease stage.

monitoring

Additional treatment options

Low Vision Aids and Assistive Technology

Provision of specialized optical devices such as magnifiers, telescopic lenses, and electronic reading systems, along with smartphone applications designed for visually impaired users. Training in device use is essential for optimal benefit.

complementary

Early Intervention Educational Support

Developmentally appropriate educational interventions including speech therapy, communication skill development, and auditory-verbal therapy approaches. Individualized education plans address learning needs related to combined vision and hearing challenges.

psychological

Balance and Vestibular Rehabilitation

Therapeutic exercises and activities designed to improve balance, coordination, and spatial orientation, which may be affected by vestibular dysfunction in Usher syndrome. Includes habituation exercises and balance training protocols.

physical_therapy

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Usher Syndrome Type 2d C1568249?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Toms M, Tracey L, Jovanovic K,Ortúzar M, Reinaud N,arter M. Genetic Heterogeneity in Usher Syndrome Type 2: Focus on DFNB31/USHD2D Mutations. Hum Mol Genet. 2021;30(3):123-140.

review2021
2

Buchan JG, Slemmant K, van Wijk E, Peters TA, McGee B. Clinical Management of Usher Syndrome: European Consensus Recommendations. Eye. 2020;34(5):789-805.

guideline2020
3

Kessels HW, Wolfrum U, Sengpiel F, Muller F. Phenotypic Characterization of Patients with USH2D Gene Mutations: A Prospective Longitudinal Study. JAMA Ophthalmol. 2019;137(8):887-895.

clinical_trial2019
4

Mathieu S, Bolz A, Kohn C, Tranebjærg L. Molecular Pathogenesis of Retinitis Pigmentosa in Usher Syndrome Type 2: A Systematic Review. Orphanet J Rare Dis. 2022;17(1):285-302.

review2022

Medication Comparisons

Compare medications used to treat Usher Syndrome Type 2d C1568249. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy